Monitoring “LONG COVID” impact on Cognition via digital neuropsychological assessment

Study Objective

The increasing evidence and understanding of SARS-CoV-2’s impact on the central nervous system (CNS) raise key questions on the impact of risk of later-life cognitive decline. Measuring cognition is essential to perceive early manifestations of brain alteration, either as a preliminary detection before any other more sophisticated and costly examination (e.g., MRI) or as a complementary diagnosis. With the recent advancements in artificial intelligence, the validated VMTech allows conducting digital neuropsychological tests, evaluating in a short amount of time, attention, memory, executive functioning, information processing speed, and visuo-spatial processing.

• The first objective of the project will consist in a validation study comparing the digital neuropsychological assessment with the gold standard.
• As a secondary objective, particular attention will be paid to cognitively stimulating activities practiced by the studied population to see whether protective factors could be identified and proposed.

Participation conditions

Inclusion criteria

• population from Predi-COVID who accepted to be contacted again for further investigation
• preferably between 30 and 60 years old
• able to complete the test independently

Exclusion criteria

• psychological or neurological disorders history especially those detected prior to the COVID-19 disease (e.g. epilepsy, stroke, chronic fatigue)
• treatment that could interfere with the assessment (e.g., antipsychotics, antidepressants, mood stabilizers,  antiepileptic’s, benzodiazepines)
• history of drug abuse or drug dependence
• an uncorrected visual impairment (less than 20/20)
• color-blindness
• any comprehension problem

 

LCTR = Luxembourg Centre for Clinical and Translational Research
LIH = Luxembourg Institute of Health